Aperçu et prévisions du marché mondial de la dépression post-partum jusqu'en 2031 - Analyse du marché et part de marché

Marché mondial de la dépression post-partum – Aperçu du secteur

La dépression post-partum (DPP) est un mélange complexe de changements physiques, émotionnels et comportementaux qui surviennent chez les femmes après l'accouchement. Il s'agit d'un sous-ensemble important de troubles de l'humeur, dont les symptômes vont de la tristesse et de l'anxiété à la dépression sévère. Le marché mondial de la dépression post-partum englobe une variété de produits, notamment des antidépresseurs , des thérapies et des suppléments naturels, tous destinés à résoudre ce problème critique de santé mentale. Selon l'American Journal of Obstetrics and Gynecology, la prévalence de la dépression post-partum (DPP) a presque doublé, passant de 9,4 % en 2010 à 19,3 % en 2021, reflétant une reconnaissance et un diagnostic croissants de la maladie. L'augmentation de la prévalence a contribué de manière significative à l'expansion du marché mondial de la DPP, car le besoin accru de traitements efficaces stimule la demande de thérapies innovantes comme la brexanolone (Zulresso) et d'autres interventions en santé mentale, conduisant à une croissance constante du marché.

Le rapport de recherche sur le marché de Data Bridge Market Research fournit des détails sur les nouveaux développements récents, la part de marché, les tendances du marché sur la base de ses segmentations et de son analyse régionale, l'impact des acteurs du marché, les analyses d'opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, l'analyse stratégique de la croissance du marché, la taille du marché, la croissance du marché des catégories, les niches d'application et la domination, les approbations de produits, les lancements de produits, les expansions géographiques, les innovations technologiques sur le marché. Pour obtenir plus d'informations sur le marché, contactez l'équipe d'analystes experts de Data Bridge Market Research. Notre équipe vous aidera à prendre des décisions de marché éclairées pour assurer la croissance de votre entreprise.

Taille du marché mondial de la dépression post-partum et analyse du marché

The decreasing stigma around mental health is playing a crucial role in the growth of the global postpartum depression (PPD) market, as more women feel empowered to seek help for PPD without fear of judgment. Shifting societal attitudes has increased demand for effective treatments and therapies, driving the market's expansion and encouraging continued innovation in addressing this critical aspect of maternal health. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Postpartum Depression Market is increasing at a CAGR of 30.25%. Our detailed analysis forecasts that the market is valued at USD 8.68 billion in 2023 and is expected to grow up to USD 55.24 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Postpartum Depression Market Dynamics

Global Postpartum Depression Market Growth Drivers

Rising investment in healthcare infrastructure

According to the World Health Organization (WHO)'s Global Health Expenditure Report 2023, global spending on health reached a record high of USD 9.8 trillion, or 10.3% of global GDP. Substantial investment enhances the availability of resources for research, treatment, and improved access to mental health services, thereby supporting the development and dissemination of effective postpartum depression therapies. Consequently, financial boost fosters the Global Postpartum Depression Market's expansion by addressing the rising demand for postpartum depression interventions.

Reduced stigma surrounding mental health

Reduced stigma surrounding mental health issues has significantly encouraged more women to seek help for postpartum depression (PPD). According to American Psychological Association, adults aged 35 to 44 saw the most significant rise in mental health diagnoses, with 45% reporting mental illness in 2023, up from 31% in 2019. Shift towards mental health awareness supports the growth of the global postpartum depression market by increasing the demand for effective treatments, interventions ad diagnoses.

Global Postpartum Depression Market Growth Opportunities

Rising number of research and development activities

The development of new therapies, such as brexanolone (Zulresso), ketamine-based therapies, and advancements in antidepressants provide new options that target different neurotransmitter systems, offering hope to the patients who may not respond to conventional medications. Digital health mobile applications for cognitive behavioral therapy (CBT) and telehealth platforms enhance the accessibility and personalization of care, allowing for real-time, remote support, and tailored treatment plans. These innovations collectively represent significant opportunities for growth in the global postpartum depression market, as they address diverse patient needs, improve treatment outcomes, and expand the reach of effective care.

Global Postpartum Depression Market Growth Challenges

High costs associated with Postpartum Depression restricting the market growth

High costs associated with postpartum depression (PPD) treatment restrict market growth by limiting access for many patients. The significant expense of this novel therapy can lead to insurance coverage challenges and out-of-pocket costs that are prohibitive for some women. Furthermore, the cost of comprehensive mental health programs and advanced treatments can strain healthcare budgets, particularly in lower-income regions. These financial barriers restrict widespread adoption and limit the growth potential of the Global Postpartum Depression Market by preventing broader access to effective care.

Global Postpartum Depression Market Growth Restraints

Lack of standardized screening

The lack of standardized screening for postpartum depression (PPD) significantly restrains the growth of the global market by leading to missed diagnoses and lower treatment rates. In regions such as Southeast Asia and Africa, where screening practices are less consistent, a substantial number of women are not identified and treated for PPD, resulting in delayed intervention and reduced treatment uptake. This inconsistency in screening impedes market growth by limiting the number of patients accessing effective treatments and creating disparities in care, ultimately constraining the expansion of the global postpartum depression market.

Regulatory hurdles

In the Global postpartum depression (PPD) market, approval delays are a major regulatory constraint that are frequently caused by the drawn-out and intricate procedures mandated by organizations such as the FDA and EMA. For instance, it took several years for the first drug licensed particularly for PPD, brexanolone (Zulresso), to get the approval. The entire process from first proposal to approval took almost ten years, despite the breakthrough status, showing how regulatory obstacles can cause delays in the availability of novel medications. Such Delays hamper the introduction of novel medicines, which can hinder the Global Postpartum Depression Market expansion.

Global Postpartum Depression Market Scope and Trends

• CAMH-developed a natural supplement to effectively prevent postpartum blues and reduce depression symptoms, with none of the supplemented group reaching the clinical threshold for postpartum depression six months post-birth.
• The use of selective serotonin reuptake inhibitors (SSRIs), such as sertraline, to treat postpartum anxiety has increased due to their proven efficacy and safety profile, particularly for breastfeeding mothers.
• For patients 22 years of age and above receiving clinician-managed outpatient care, the FDA authorized MamaLift Plus as a prescription-only digital therapeutic. It is meant to be used for eight weeks in order to treat mild to moderate postpartum depression.

Global Postpartum Depression Market Regional Analysis- Market Trends

Key Insights

• North America leads the global postpartum depression (PPD) market, driven by advanced healthcare infrastructure, high awareness, and substantial investment in mental health. The U.S., in particular, dominates with widespread screening programs and access to innovative treatments like brexanolone (Zulresso).
• Europe is a key contributor to the growing global postpartum depression (PPD) market, driven by increased awareness, government initiatives, and robust healthcare infrastructure. Widespread screening programs support early diagnosis and treatment. Ongoing research and development in Europe further fuel market expansion with the introduction of new therapies.
• The Asia Pacific region offers significant growth potential for the global postpartum depression (PPD) market, driven by increasing awareness, improving healthcare infrastructure, and rising mental health education. As countries like China, Japan, and India recognize the importance of maternal mental health, demand for PPD treatments is expanding.
• En Afrique, le marché mondial de la dépression post-partum (DPP) se développe à mesure que la sensibilisation et les ressources en matière de santé mentale s'améliorent. La reconnaissance croissante de la DPP, ainsi que l'expansion des infrastructures de santé et des options de traitement abordables, stimulent la croissance du marché dans la région. L'Afrique apparaît comme une opportunité clé pour le marché mondial de la DPP.

Principaux acteurs du marché mondial de la dépression post-partum

• Pfizer Inc. (États-Unis)
• GlaxoSmithKline plc (Royaume-Uni)
• Novartis SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson Private Limited (États-Unis)
• Bayer AG (Allemagne)
• Merck & Co., Inc. (États-Unis)
• Hoffmann-La Roche SA (Suisse)
• Eli Lilly and Company (États-Unis)
• Cipla Inc. (États-Unis)
• Aurobindo Pharma (Inde)
• Lupin (Inde)
• Accord Healthcare (États-Unis)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Les Compagnies de Santé Bausch Inc. (Canada)
• Alvogen (États-Unis)
• Intas Pharmaceuticals Ltd. (Inde)
• SHIONOGI & Co., Ltd. (Japon)

Développements récents du marché mondial de la dépression post-partum

• En août 2024, la Food and Drug Administration américaine a rejeté la psychothérapie MDMA pour le SSPT (trouble de stress post-traumatique).
• En juillet 2024, la découverte du rôle du gène TRPC5 dans l'obésité et la dépression postnatale offre l'espoir de nouveaux traitements.
• En juillet 2023, le groupe de travail des services de prévention des États-Unis (USPSTF) a mis à jour ses directives pour recommander un dépistage universel de la PPD pendant et après la grossesse, améliorant ainsi la détection et l'intervention précoces.
• En janvier 2024, la campagne « La santé mentale maternelle est importante », lancée par l’Organisation mondiale de la santé (OMS), vise à accroître la sensibilisation et le soutien à la dépression post-partum à l’échelle mondiale, en soulignant l’importance de la santé mentale pendant la période post-partum.
• En 2024, plusieurs nouvelles plateformes numériques et applications mobiles, telles que Perinatal Support , ont été introduites, offrant une thérapie virtuelle et un soutien en matière de santé mentale basé sur l'IA, spécialement adaptés aux femmes en post-partum.

SKU-53538